



(11) **EP 1 133 312 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Bibliography INID code(s) 84**
- (51) Int Cl.:  
**A61K 38/22** (2006.01) **A61K 38/26** (2006.01)  
**A61P 3/08** (2006.01) **A61K 31/425** (2006.01)
- (48) Corrigendum issued on:  
**17.10.2007 Bulletin 2007/42**
- (86) International application number:  
**PCT/US2000/015548**
- (45) Date of publication and mention  
of the grant of the patent:  
**12.09.2007 Bulletin 2007/37**
- (87) International publication number:  
**WO 2000/078333 (28.12.2000 Gazette 2000/52)**
- (21) Application number: **00938173.2**
- (22) Date of filing: **06.06.2000**

(54) **SYNERGISTIC USE OF THIAZOLIDINEDIONES WITH GLUCAGON-LIKE PEPTIDE-1 AND AGONISTS THEREOF TO TREAT NON-INSULIN DEPENDENT DIABETES**

SYNERGITISCHE VERWENDUNG VON THIAZOLIDINEDIONEN UND GLUCAGON-ÄHNLICHEM PEPTID-1 UND DESSEN AGONISTEN FÜR DIE BEHANDLUNG VON NICHT-INSULIN-ABHÄNGIGEN DIABETES

UTILISATION COMBINEE DE THIAZOLIDINEDIONES ET DE PEPTIDE-1 DE TYPE GLUCAGONE ET D'AGONISTES DE CES DERNIERS POUR TRAITER DIABETES NON INSULINO-DEPENDANT.

- |   |  |
|---|--|
| <p>(84) Designated Contracting States:<br/><b>AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE</b><br/>Designated Extension States:<br/><b>AL LT LV MK RO SI</b></p> <p>(30) Priority: <b>21.06.1999 US 139794 P</b></p> <p>(43) Date of publication of application:<br/><b>19.09.2001 Bulletin 2001/38</b></p> <p>(60) Divisional application:<br/><b>07111988.7</b></p> <p>(73) Proprietor: <b>ELI LILLY AND COMPANY</b><br/><b>Indianapolis, Indiana 46285 (US)</b></p> <p>(72) Inventors:<br/>• <b>YAKUBU-MADUS, Fatima, Emitsel</b><br/><b>Indianapolis, IN 46256 (US)</b></p> | <ul style="list-style-type: none"><li>• <b>STRAMM, Lawrence, E.</b><br/><b>Indianapolis, IN 46256 (US)</b></li><li>• <b>JOHNSON, William, T.</b><br/><b>Indianapolis, IN 46227 (US)</b></li><li>• <b>VIGNATI, Louis</b><br/><b>Indianapolis, IN 46208 (US)</b></li></ul> <p>(74) Representative: <b>Burnside, Ivan John</b><br/><b>Eli Lilly and Company Limited</b><br/><b>Lilly Research Centre</b><br/><b>Erl Wood Manor</b><br/><b>Windlesham, Surrey GU20 6PH (GB)</b></p> <p>(56) References cited:<br/><b>EP-A- 0 733 644 WO-A-00/00195</b><br/><b>WO-A-98/57636 WO-A-99/03478</b><br/><b>US-A- 5 631 224</b></p> <ul style="list-style-type: none"><li>• <b>REASNER, C. A., II: "Promising new approaches"</b><br/><b>DIABETES, OBES. METAB. (1999), 1(SUPPL. 1),</b><br/><b>S41-S48 , XP000971954</b></li></ul> |
|---|--|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 133 312 B8**